|
Match
|
Document |
Document Title |
|
|
6043225 |
Diagnosis and treatment of arterial chlamydial granuloma
Method of diagnosing arterial chlamydial granuloma by detecting in a biological sample both a first marker associated with Chlamydia pneumoniae and a second marker associated with arterial...
|
|
|
6043227 |
C11 carbamates of macrolide antibacterials
This invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are potent antibacterial agents that may be used to treat...
|
|
|
6043226 |
3,6-ketal and enol ether macrolide antibiotics
This invention relates to compounds of formulas 1 and 2 ##STR1## and to pharmaceutically acceptable salts and solvates thereof, wherein X, X 1 , R 1 , R 2 , R 7 , R 17 and R 19 are as defined...
|
|
|
6034069 |
3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
Novel 3'-N-modified 6-O-substituted erythromycin ketolide compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula ##STR1## compositions...
|
|
|
6017894 |
Actinomadura fulva subsp uruguayensis and antimicrobial complex and antimicrobial compounds isolated therefrom
Three novel macrolactam monosaccharides isolated from an antimicrobial complex 510 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism...
|
|
|
5985844 |
Homoerythromycin A derivatives modified at the 4"-and 8A-positions
Compounds of the formula: ##STR1## where R is hydrogen, hydroxyl, alkyl or acyl, R' and R" together are oxo, hydroxyimino or alkoxyimino, and R' and R" independently are hydrogen, hydroxyl,...
|
|
|
5981499 |
Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
The invention provides a medicament for topically treating aphthous ulcers in the oral mucosa, and methods of use. The medicament comprises a troche or powder comprising a dry dosage of one or more...
|
|
|
5972898 |
3',3-N-bis-substituted macrolide LHRH antagonists
Disclosed are 3',3'-N-bisdesmethyl-3',3'-N-bis-substituted-6-O-methyl-11-d
eoxy-11,12-cyc lic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone...
|
|
|
5955440 |
Macrolide LHRH antagonists
Disclosed are 3'-N-desmethyl-3'-N-substituted-6-O-methyl-11-deoxy-11,12-cy
clic carbamate erythromycin A derivatives which are antagonists of lutenizing hormone-releasing hormone (LHRH). Also...
|
|
|
5945405 |
Crystal form O of clarithromycin
The present invention concerns the novel antiobiotic 6-O-methylerythromycin A form O solvate, a process for its preparation, pharmaceutical compositions comprising this compound and a method of use...
|
|
|
5922683 |
Multicyclic erythromycin derivatives
Novel multicyclic erythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula ##STR1## pharmaceutical compositions comprising a...
|
|
|
5897877 |
Oral pharmaceutical preparation containing erythromycin base
Basic pellets containing erythromycin base, to which a small amount of a slightly acid salt, such as potassium dihydrogen phosphate and possibly an additive is added for improved release of the...
|
|
|
5885601 |
Use of macrolide antibiotics for nonsurgical female sterilization and endometrial ablation
The present invention relates to a method of female sterilization including delivery of a macrolide antibiotic or a pharmacologically acceptable salt of a macrolide antibiotic to the uterine cavity...
|
|
|
5883074 |
Potentiators of antibacterial agents
Methods for screening for compounds which potentiate the activity of antibacterial agents against bacteria resistant to the antibacterial agent alone, pharmaceutical compositions including such...
|
|
|
5880101 |
Clinical uses of polyene macrolides
The present invention relates to the use of at least one polyene macrolide for the preparation of pharmaceutical compositions for the treatment of diseases that are associated with an impaired...
|
|
|
5872104 |
Combinations and methods for reducing antimicrobial resistance
Disclosed are novel methods, combinations of agents and kits for use in killing, or inhibiting the growth of, microorganisms. Enhanced antimicrobial action is provided by using a methylation...
|
|
|
5858986 |
Crystal form I of clarithromycin
The present invention concerns the novel antiobiotic 6-O-methylerythromycin A crystal form I, a process for its preparation, pharmaceutical compositions comprising this compound and a method of use...
|
|
|
5854219 |
9-N-ethenyl derivatives of 9(S)-erythromycylamine
The invention relates to 9-N-ethenyl derivatives of 9 (S)-erythromycylamine, new semisynthetic antibiotics of the macrolide class of the general formula (I) ##STR1## wherein R 1 and R 2 are the...
|
|
|
5837691 |
Actinomadura vulgaris subsp vulgaris and antimicrobial complex and antimicrobial
A novel macrolactam monosaccharide isolated from an antimicrobial complex 517 produced in fermentation under controlled conditions using a biologically pure culture of the microorganism...
|
|
|
5834438 |
4"-deoxyerythromycin derivatives
4"-Deoxy derivatives of erythromycin having the Formula (I) ##STR1## and pharmaceutically acceptable salts thereof, which are enhancers of gastric motility but have minimal antibacterial activity,...
|
|
|
5830874 |
Compositions and methods for the treatment of arterial chlamydial granuloma
Method of diagnosing arterial chlamydial granuloma by detecting in a biological sample both a first marker associated with Chlamydia pneumoniae and a second marker associated with arterial...
|
|
|
5827543 |
Methods and compositions for the prevention and treatment of urogenital disorders
The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa...
|
|
|
5824513 |
Recombinant DNA method for producing erythromycin analogs
A method to produce novel polyketide structures by designing and introducing specified changes in the DNA governing the synthesis of the polyketide is disclosed. The biosynthesis of specific...
|
|
|
5795897 |
Oxohexyl methylxanthine compounds
There is disclosed a pharmaceutical composition comprising 1-(5-oxohexyl)-3-methylxanthine in admixture with a pharmaceutically acceptable excipient, wherein the pharmaceutical composition is...
|
|
|
5795871 |
Pharmaceutical composition for treatment of non-small cell lung cancer
14- or 15-membered-ring macrolide compounds such as clarithromycin, erythromycin B, etc. have a potent antitumor effect on non-small cell lung cancers which are considered the most difficult tumors...
|
|
|
5786338 |
Method of treating hypercholesterolemia with a macrolide antibiotic
This invention is directed to a novel method for treating human patients with hypercholesterolemia with a macrolide antibiotic. More specifically, this invention is directed to the oral...
|
|
|
5786181 |
Process for producing high purity 6, 12-dideoxyerythromycin A by fermentation
A process for producing high purity 6,12-dideoxyerythromycin A using recombinant DNA technology is disclosed. The erythromycin producing strain, Saccharopolyspora erythraea, lacking the...
|
|
|
5760010 |
Method of treating liver disorders with a macrolide antibiotic
This invention is directed to a novel method for treating humans with liver diseases or liver disorders with a macrolide antibiotic. Many different liver disorders can be treated with the claimed...
|
|
|
5756473 |
6-O-methyl erythromycin D and process for making
An antibacterial compound is disclosed having the formula: ##STR1## wherein R 1 is loweralkyl or a pharmaceutically acceptable salt, ester or prodrug thereof, processes and intermediates useful in...
|
|
|
5750510 |
3-descladinose-2,3-anhydroerythromycin derivatives
Novel 3-descladinose-2,3-anhydroerythromycin compounds and pharmaceutically acceptable salts and esters thereof having antibacterial activity.
|
|
|
5750493 |
Method to improve the biological and antiviral activity of protease inhibitors
Methods for improving the cellular uptake of protease inhibitors (e.g., HIV protease inhibitor), alone or in the presence of one or more additional therapeutic agents, in protease inhibitor-based...
|
|
|
5747466 |
3-deoxy-3-descladinose derivatives of erythromycins A and B
A compound selected from the group: ##STR1## wherein A, B, V, W, X and R 8 are specifically defined; pharmaceutical compositions thereof; a method of treating or preventing bacterial infections by...
|
|
|
5723447 |
Water miscible erythromycin solutions
Water miscible pharmaceutical compositions containing up to about 40% of erythromycin prepared by reaction with acetic acid in a non-aqueous water miscible organic solvent system.
|
|
|
5712253 |
Macrocyclic 13-membered ring derivatives of erythromycins A and B
Novel macrocyclic 13-membered ring-contracted compounds derived from erythromycins A and B having the Formula (I) ##STR1## and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 , R 3 ...
|
|
|
5674858 |
Medicaments for treating gastrointestinal disorders
The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders. Pharmaceutical...
|
|
|
5658887 |
Pharmaceutical formulations comprising a clavulanic acid salt and erithromycin derivatite
A pharmaceutical formulation comprising a pharmaceutically acceptable salt of clavulanic acid in combination with erythromycin and another antimicrobial agent useful for the treatment of an...
|
|
|
5658888 |
Erythromycin derivatives
Compounds represented by the general formula: ##STR1## wherein R 1 is a hydrogen atom or an acyl group; R 2 and R 3 may be the same or different, and each represents a hydrogen atom, hydroxyl...
|
|
|
5656607 |
Erythromycin derivatives
A compound selected from the group consisting of a compound of the formula ##STR1## wherein R 1 and R 2 are individually selected from the group consisting of hydrogen and an optionally...
|
|
|
5650394 |
Use of urinastatin-like compounds to prevent premature delivery
The present invention provides a method of diagnosing and treating a pregnant female at risk for impending preterm delivery. The method comprises the step of diagnosing imminent preterm delivery by...
|
|
|
5641753 |
10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives combined with sulfisoxazole
Pharmaceutical compositions of an erythromycin derivative combined with sulfisoxazole according to the structural formulas: ##STR1## where R is hydrogen, C1-C10 alkylcarbonyl or C1-C10 alkyl...
|
|
|
5637616 |
Method for treating diseases mediated by proteases
A method for the topical or systemic treatment of disorders mediated by proteases which result in skin or mucosal lesions, and in particular, pemphigus, cicatricial pemphigoid, bullous pemphigoid,...
|
|
|
5629296 |
9A-N-(N'-carbamoyl)and 9A-N-(N'-thiocarbamoyl) derivatives of 9-deoxo-9A-aza-9A-homoerythromycin A
The invention relates to 9a-N-(N'-carbamoyl) and 9a-N-(N'-thiocarbamoyl) derivatives of 9-deoxo-9a-aza-9a-homoerythromycin A, novel semisynthetic macrolide antibiotics of the azalide series, of the...
|
|
|
5578580 |
Veterinary composition, feedstuff and process
A veterinary composition in form of sustained release microcapsules containing erythromycin thiocyanate as active ingredient is disclosed. In the use, said composition is mixed with standard...
|
|
|
5559098 |
Stable topical formulations with good active ingredient release characteristics, containing at least one lipophilized macrolide antibiotic
A stable topical formulation with good active ingredient release characteristics, comprising at least one macrolide antibiotic which is lipophilized with at least one former of oppositely charged...
|
|
|
5556839 |
Form II Dirithromycin
The invention provides Form II dirithromycin, a novel polymorph of dirithromycin. Also disclosed are the acetone, 1-butanol, 1-propanol, and 2-propanol solvates of dirithromycin, which provide an...
|
|
|
5529994 |
Treatment for toxoplasmosis
A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or...
|
|
|
5472946 |
Transdermal penetration enhancers
This invention relates to compounds and a method for their use in carrying physiologically active agents through body membranes such as skin and for retaining these agents in body tissues. More...
|
|
|
5466446 |
Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
Dermatological conditions are treated by topically applying to the affected area an effective amount of a combination benzoyl peroxide and clindamycin composition.
|
|
|
5441939 |
3"-desmethoxy derivatives of erythromycin and azithromycin
A compound having the formula ##STR1## wherein Z is CH 2 --N(CH 3 ), N(CH 3 )--CH 2 , or ##STR2## R 1 and R 2 are selected from 1) one of R 1 and R 2 is OH and the other of R 1 and R 2 is (C...
|
|
|
5434140 |
9-deoxo-9a-aza-11-deoxy-9a-homoerythromycin a 9a,11-cyclic carbamates
The invention relates to 9-deoxo-9a-aza-11-deoxy-9a-homoerythromycin A 9a,11-cyclic carbamates, novel semisynthetic macrolide antibiotics from the genus of azalides, of the formula (I) ##STR1##...
|